Skip to content

Clinical Study of Acupuncture Combined with Moxibustion in the treatment of Chemotherapy induced Peripheral Neuropathy

Clinical Study of Acupuncture Combined with Moxibustion in the treatment of Chemotherapy induced Peripheral Neuropathy

Status
Unknown
Phases
Phase 1
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230112003
Enrollment
100
Registered
2023-01-12
Start date
2023-02-10
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy, which has a serious impact on the quality of life of patients. At present, there is no targeted and reliable treatment plan. To investigate the efficacy and safety of acupuncture combined with moxibustion in the treatment of CIPN, a randomized controlled trial was conducted. Acupuncture

Interventions

Acupuncture point selection: Hegu (LI4), Taichong (LR3), Quchi (PC3), Neiguan (PC6), Zusanli (ST36), Xuehai (SP10), Fenglong (ST40), Yanglingquan (GB34), Shixuan (EX-UE11), Sanyinjiao (SP6), Taixi (KI
s Republic of China, Meridian Points Locations [29], and the treatment was completed by professional acupuncturists with more than 5 years of acupuncture and moxibustion experience, and the treatment
Experimental Other
acupuncture combined with moxibustion

Sponsors

Weiyu Chang and Lijiang Ji
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Have received chemotherapy (complete at least one complete cycle), the primary disease condition is stable; (2) Symptoms of chemotherapy-induced peripheral neuropathy after the end of chemotherapy; (3) Age not less than18 years and not more than80 years; (4) Karnofsky's performance status (KPS) score was greater than 60; (5) Predicted survival time not less than 6 months; (6) The patient has signed informed consent.

Exclusion criteria

Exclusion criteria: (1) A history of neuropathy, such as diabetes, multiple sclerosis, HIV and Parkinson's disease; (2) Patients with a variety of drug allergy or allergic constitution; (3) Patients with other neurological diseases, which may affect the evaluation of efficacy; (4) Patients with skin damage or infection at the acupoints that were not suitable for acupuncture or moxibustion; (5) Patients suffering from mental illness.

Design outcomes

Primary

MeasureTime frame
TNS , including 11 scoring items. 4 weeks evaluate the symptoms and signs of peripheral neuropathy, motor and sensory neurophysiology examination, touch, vibration perception, quality of life, etc.

Secondary

MeasureTime frame
evaluate the symptoms and signs of peripheral neuropathy, motor and sensory neurophysiology examination, touch, vibration perception, quality of life, etc. 4 weeks ranging from grade 0 to grade 4

Countries

China

Contacts

Public ContactLijiang Ji

Changshu Hospital Affiliated to Nanjing University of Chinese Medicine, Changshu, Jiangsu province, China

Ji512@163.com18233601242

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026